Prostate Cancer

>

CURE’s prostate cancer page is an extensive resource of cancer information featuring the latest prostate cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on prostate cancer.

Latest News

Photo of a patient in consultation with a doctor.
Decipher Prostate Test Now Available for Metastatic Prostate Cancer

April 25th 2025

Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.

The first patient has been enrolled in the ARID II trial for prostate cancer: stock.adobe.com.
First Patient Enrolled in ARID II Trial for Prostate Cancer Treatment

April 24th 2025

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset

April 15th 2025

Image of man.
Nubeqa Combo Improves Outcomes in Metastatic Prostate Cancer

April 15th 2025

Image of man and doctor.
NeuroSAFE May Increase Erectile Function After Prostate Cancer Surgery

April 12th 2025

Educated Patient Resource Guide

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Resource guide for prostate cancer

More News

Coalition to Focus on Health Disparities Black Men with Prostate Cancer Face

Coalition to Focus on Health Disparities Black Men with Prostate Cancer Face

Beth Fand Incollingo
September 28th 2020

Forward Momentum, a coalition launched by a biopharmaceutical company and three partners, focuses on the health disparities faced by Black men with prostate cancer.

Advances in Prostate Cancer

Advances in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Future Use of PARP Inhibition in Prostate Cancer

Future Use of PARP Inhibition in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Advice to Patients Facing mCRPC

Advice to Patients Facing mCRPC

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
PARP Inhibitors in Recurrent mCRPC

PARP Inhibitors in Recurrent mCRPC

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Treatment Options Available for mCRPC

Treatment Options Available for mCRPC

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
John Litten: Participating on a PARP Clinical Trial for mCRPC

John Litten: Participating on a PARP Clinical Trial for mCRPC

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Talking About Gene Testing in Prostate Cancer

Talking About Gene Testing in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Testing for Mutations in Prostate Cancer

Testing for Mutations in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Prostate Cancer: Learning About Treatment Options

Prostate Cancer: Learning About Treatment Options

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Receiving a Prostate Cancer Diagnosis

Receiving a Prostate Cancer Diagnosis

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Metastatic Castration-Resistant Prostate Cancer Overview

Metastatic Castration-Resistant Prostate Cancer Overview

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
The Future of PARP Inhibitors in Prostate Cancer

The Future of PARP Inhibitors in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Patient’s Role in Decision-Making for Prostate Cancer

Patient’s Role in Decision-Making for Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Quality of Life With Prostate Cancer

Quality of Life With Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
FDA-Approved PARP Inhibitors for Prostate Cancer

FDA-Approved PARP Inhibitors for Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Impact of BRCA Mutations in Prostate Cancer

Impact of BRCA Mutations in Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Genetic Counseling for Prostate Cancer

Genetic Counseling for Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Diagnosis of Prostate Cancer

Diagnosis of Prostate Cancer

Alan H. Bryce, MD, Mayo Clinic;John Litten, Patient & Advocate
September 28th 2020
Smartphone App Encourages Smoking Cessation, House Passes Veteran’s Prostate Cancer Treatment and Research Act, and More

Smartphone App Encourages Smoking Cessation, House Passes Veteran’s Prostate Cancer Treatment and Research Act, and More

Conor Killmurray
September 25th 2020

From a new study showing that the iCanQuit smoking cessation app is more likely to work than typical guidelines, to the House unanimously passing the Veteran’s Prostate Cancer Treatment and Research Act, here’s what’s happening in the cancer landscape this week.

Lynparza Significantly Improves Survival in Subset of Patients with Metastatic Prostate Cancer

Lynparza Significantly Improves Survival in Subset of Patients with Metastatic Prostate Cancer

Kristie L. Kahl
September 23rd 2020

The PARP inhibitor Lynparza reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer compared with Xtandi or Zytiga plus the corticosteroid prednisone.

The Future of PARP Inhibitors in Prostate Cancer

The Future of PARP Inhibitors in Prostate Cancer

Nicholas J. Vogelzang, MD, FASCO, FACP, Comprehensive Cancer Centers of Nevada
September 16th 2020
Patient’s Role in Decision-Making for Prostate Cancer

Patient’s Role in Decision-Making for Prostate Cancer

Nicholas J. Vogelzang, MD, FASCO, FACP, Comprehensive Cancer Centers of Nevada
September 16th 2020
Quality of Life With Prostate Cancer

Quality of Life With Prostate Cancer

Nicholas J. Vogelzang, MD, FASCO, FACP, Comprehensive Cancer Centers of Nevada
September 16th 2020
FDA Approved PARP Inhibitors for Prostate Cancer

FDA Approved PARP Inhibitors for Prostate Cancer

Nicholas J. Vogelzang, MD, FASCO, FACP, Comprehensive Cancer Centers of Nevada
September 16th 2020
Impact of BRCA Mutations in Prostate Cancer

Impact of BRCA Mutations in Prostate Cancer

Nicholas J. Vogelzang, MD, FASCO, FACP, Comprehensive Cancer Centers of Nevada
September 16th 2020
Genetic Counseling for Prostate Cancer

Genetic Counseling for Prostate Cancer

Nicholas J. Vogelzang, MD, FASCO, FACP, Comprehensive Cancer Centers of Nevada
September 16th 2020
Diagnosis of Prostate Cancer

Diagnosis of Prostate Cancer

Nicholas J. Vogelzang, MD, FASCO, FACP, Comprehensive Cancer Centers of Nevada
September 16th 2020
CURE® Speaking Out Launches Video Series in Recognition of National Prostate Cancer Awareness Month

CURE® Speaking Out Launches Video Series in Recognition of National Prostate Cancer Awareness Month

CURE staff
September 8th 2020

Charles J. Ryan, M.D., internationally recognized for his research on prostate cancer, discusses risk factors, treatments and racial disparities associated with the disease.

The Latest News and Updates in Prostate Cancer

The Latest News and Updates in Prostate Cancer

CURE staff
September 5th 2020

A roundup of the latest news and updates for patients with prostate cancer from CURE®.

<1
...
91011121314151617
...
27>